Access Bio Inc (950130) - Total Liabilities

Latest as of June 2025: ₩67.08 Billion KRW ≈ $45.46 Million USD

Based on the latest financial reports, Access Bio Inc (950130) has total liabilities worth ₩67.08 Billion KRW (≈ $45.46 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 950130 cash flow metrics to assess how effectively this company generates cash.

Access Bio Inc - Total Liabilities Trend (2012–2024)

This chart illustrates how Access Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Check 950130 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Access Bio Inc Competitors by Total Liabilities

The table below lists competitors of Access Bio Inc ranked by their total liabilities.

Company Country Total Liabilities
The Hi-Tech Gears Limited
NSE:HITECHGEAR
India Rs3.14 Billion
Spring Valley Acquisition Corp. II Class A Ordinary Shares
NASDAQ:SVII
USA $5.87 Million
Aspen Group Ltd
TA:ASGR
Israel ILA2.90 Billion
Synergy Innovation Co. Ltd
KQ:048870
Korea ₩67.50 Billion
Aminex PLC
STU:DOP
Germany €15.15 Million
Kunyue Development Co Ltd
TWO:5206
Taiwan NT$13.79 Billion
Asuransi Multi Artha Guna Tbk PT
JK:AMAG
Indonesia Rp3.46 Trillion
Midas Minerals Ltd
AU:MM1
Australia AU$287.49K

Liability Composition Analysis (2012–2024)

This chart breaks down Access Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 950130 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 15.67 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.11 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.10 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Access Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Access Bio Inc (2012–2024)

The table below shows the annual total liabilities of Access Bio Inc from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 ₩61.70 Million
≈ $41.81K
-99.94%
2023-12-31 ₩104.00 Billion
≈ $70.48 Million
+49192.84%
2022-12-31 ₩210.97 Million
≈ $142.97K
+60.93%
2021-12-31 ₩131.10 Million
≈ $88.84K
+64.97%
2020-12-31 ₩79.47 Million
≈ $53.86K
+103.73%
2019-12-31 ₩39.01 Million
≈ $26.43K
-24.11%
2018-12-31 ₩51.40 Million
≈ $34.83K
+11.67%
2017-12-31 ₩46.03 Million
≈ $31.19K
+5.38%
2016-12-31 ₩43.68 Million
≈ $29.60K
-98.97%
2015-12-31 ₩4.24 Billion
≈ $2.87 Million
-59.04%
2014-12-31 ₩10.35 Billion
≈ $7.01 Million
+15.08%
2013-12-31 ₩8.99 Billion
≈ $6.09 Million
+21.79%
2012-12-31 ₩7.38 Billion
≈ $5.00 Million
--

About Access Bio Inc

KQ:950130 Korea Diagnostics & Research
Market Cap
$125.38 Million
₩185.01 Billion KRW
Market Cap Rank
#18319 Global
#917 in Korea
Share Price
₩5260.00
Change (1 day)
-1.31%
52-Week Range
₩4790.00 - ₩6510.00
All Time High
₩29950.00
About

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities wi… Read more